



# FDA Approval Decisions Report December-February 2008

**Jeremy Zhou**  
Senior Analyst  
415-782-0454, x158  
jzhou@reveredata.com

**Daniel Grundig**  
Analyst  
415-782-0454, x176  
dgrundig@reveredata.com

## Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

## Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

---

Copyright 2007 by Revere Data, LLC. All rights reserved.

### Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

### Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

**For more information on Revere's independent research data and investment analytics, please contact us as follows:**

**Revere Data, LLC** | 60 East 42nd St. Suite 716 | New York, NY 110165  
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

## Recent Approval Results/Updates

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
<b>Mylan Inc. (MYL) / Nebivolol</b>				
	Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	11/01/2007	Result Pending
<b>Forest Laboratories, Inc. (FRX) / Bertek Nebivolol</b>				
	Hypertension	Beta Adrenergic Receptor Blocking Agents (Beta Blockers)	11/01/2007	Result Pending
<b>GlaxoSmithKline plc (ADR) (GSK) / Variza (Gepirone ER)</b>				
	Major Depression Disorder (MDD)	Serotonin Receptor Agonists	<u>11/02/2007</u>	<b>Non-Approvable Letter Received</b> 11/02/2007
<b>Sciele Pharma Inc. (SCRX) / Controlled Release Sular (Nisoldipine)</b>				
	Hypertension	Calcium Channel Blocking Agents	<u>11/02/2007</u>	<b>Rescheduled to</b> 01/02/2008
<b>sanofi-aventis (ADR) (SNY) / Pentacel</b>				
	Combination Vaccine For Diphtheria, Tetanus, Pertussis, Polio, Haemophilus influenzae type b (Hib) In Children	Bacterial/Viral	<u>11/02/2007</u>	Result Pending
<b>SkyePharma PLC (ADR) (SKYEY) / Controlled Release Sular (Nisoldipine)</b>				
	Hypertension	Calcium Channel Blocking Agents	<u>11/02/2007</u>	<b>Rescheduled to</b> 01/02/2008
<b>Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)</b>				
	Major Depressive Disorder (MAD) In Adults As Adjunctive To Antidepressant Therapy	Serotonin/Dopamine Receptor Partial Agonists	11/16/2007	<b>Approved</b> 11/20/2007
<b>Impax Laboratories Inc. (IPXL) / Impax Pharmaceuticals Vadova (Carbidopa/Levodopa)</b>				
	Idiopathic Parkinson's Disease, Post-Encephalitic Parkinsonism, Symptomatic Parkinsonism	Dopamine Receptor Agonists	11/16/2007	Result Pending
<b>BioMarin Pharmaceutical Inc. (BMRN) / Kuvan (Sapropterin Dihydrochloride)/FormerlyPhenoptin</b>				
	Phenylketonuria (PKU)	Enzyme Cofactors	<u>11/23/2007</u>	<b>Rescheduled to</b> 12/14/2007
<b>Fresenius Medical Care AG &amp; Co. (ADR) (FMS) / PhosLo (Calcium Acetate)</b>				
	Hyperphosphatemia In Stage 4 Chronic Kidney Disease Patients	Phosphate Binding Agents	11/23/2007	Result Pending
<b>Pipex Pharmaceuticals, Inc. (PP) / Coprexa (Oral Tetrathiomolybdate)</b>				
	Wilson's Disease	Chelating Agents	11/28/2007	Result Pending
<b>Regeneron Pharmaceuticals, Inc. (REGN) / Riloncept (Interleukin-1 Cytokine Trap)</b>				
	CIAS1-Associated Periodic Syndrome (CAPS)	Interleukin-1 Receptor Antagonists (IL-1 Antagonists)	11/30/2007	<b>Rescheduled to</b> 02/29/2008
<b>Onyx Pharmaceuticals, Inc. (ONXX) / Nexavar (Sorafenib)</b>				
	Unresectable Hepatocellular Carcinoma (Liver Cancer)	Raf Kinase Inhibitors/Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)	12/26/2007	<b>Approved</b> 11/19/2007
<b>Bayer AG (ADR) (BAYRY) / Nexavar (Sorafenib)</b>				
	Unresectable Hepatocellular Carcinoma (Liver Cancer)	Raf Kinase Inhibitors/Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFR)	12/26/2007	<b>Approved</b> 11/19/2007

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.


## Expected PDUFA Dates in the Next Three Months

### December Drug Candidates

#### Companies

BioMarin Pharmaceutical Inc. (BMRN)  
 DOV Pharmaceutical, Inc. (DOVP)  
 Jazz Pharmaceuticals, Inc. (JAZZ)  
 Ligand Pharmaceuticals Inc. (LGND)  
 Neurocrine Biosciences, Inc. (NBIX)  
 Pharmacyclics, Inc. (PCYC)  
 Solvay S.A. (ADR) (SVYSY)  
 Wyeth (WYE)

#### Sectors

**I** Biopharmaceuticals  


#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Ligand Pharmaceuticals Inc. (LGND) / Viviant (Bazedoxifene)</b>						
	Prevention Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	December 2007	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Wyeth (WYE) / Viviant (Bazedoxifene)</b>						
	Prevention Of Postmenopausal Osteoporosis	Selective Estrogen Receptor Modulators (SERM)	December 2007	Yes	<b>No</b> Multiple Drugs	No
<b>Neurocrine Biosciences, Inc. (NBIX) / Indiplon Immediate Release Capsule</b>						
	Primary (Chronic) And Transient Insomnia	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	<u>12/12/2007</u>	Yes	<b>No</b> Multiple Drugs	Yes
<b>DOV Pharmaceutical, Inc. (DOVP) / Indiplon Immediate Release Capsule</b>						
	Primary (Chronic) And Transient Insomnia	Gamma-Aminobutyric Acid (GABA) Receptor Agonists	<u>12/12/2007</u>	Yes	<b>No</b> Multiple Drugs	Yes
<b>BioMarin Pharmaceutical Inc. (BMRN) / Kuvan (Sapropterin Dihydrochloride)/FormerlyPhenoptin</b>						
	Phenylketonuria (PKU)	Enzyme Cofactors	<u>12/14/2007</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Luvox CR (Fluvoxamine Controlled Release)</b>						
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>12/21/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Jazz Pharmaceuticals, Inc. (JAZZ) / Luvox CR (Fluvoxamine Controlled Release)</b>						
	Obsessive Compulsive Disorder (OCD) And Social Anxiety Disorder (SAD)	Selective Serotonin Reuptake Inhibitors (SSRI)	<u>12/21/2007</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Pharmacyclics, Inc. (PCYC) / XCYTRIN (Motexafin Gadolinium)</b>						
	Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases	Chemo/Radiation Sensitizer	<u>12/31/2007</u>	No	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## January Drug Candidates

### Companies

Biogen Idec Inc. (BIIB)  
 Cardiome Pharma Corp.(USA) (CRME)  
 Elan Corporation, plc (ADR) (ELN)  
 GlaxoSmithKline plc (ADR) (GSK)  
 Johnson & Johnson (JNJ)  
 MiddleBrook Pharmaceuticals, Inc. (MBRK)  
 Omrix Biopharmaceuticals, Inc. (OMRI)  
 Progenics Pharmaceuticals, Inc. (PGNX)  
 Roche Holding Ltd. (ADR) (RHHBY)  
 Sciele Pharma Inc. (SCRX)  
 SkyePharma PLC (ADR) (SKYEY)  
 Solvay S.A. (ADR) (SVYSY)  
 Spectrum Pharmaceuticals, Inc. (SPPI)  
 Wyeth (WYE)  
 ZymoGenetics, Inc. (ZGEN)

### Sectors

- I Biopharmaceuticals
  - Cardiovascular System
  - Digestive System
  - Immunology
  - Infectious Diseases
  - Oncology
  - Surgery
- I Medical Devices
  - General Surgery

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>SkyePharma PLC (ADR) (SKYEY) / Controlled Release Sular (Nisoldipine)</b>						
	Hypertension	Calcium Channel Blocking Agents	<u>01/02/2008</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Sciele Pharma Inc. (SCRX) / Controlled Release Sular (Nisoldipine)</b>						
	Hypertension	Calcium Channel Blocking Agents	<u>01/02/2008</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Omrix Biopharmaceuticals, Inc. (OMRI) / Evicel (Liquid Fibrin Sealant)</b>						
	Fibrin Sealant For Hemostasis (Bleeding Control) During Kidney Surgery And General Surgical Procedures	Topical	<u>01/08/2008</u>	Yes	<b>No</b> Multiple Drugs	No
<b>Spectrum Pharmaceuticals, Inc. (SPPI) / ISO-vorin (Levofolinic Acid)</b>						
	Osteosarcoma (Bone Cancer)	Folic Acid Derivatives	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes
<b>Biogen Idec Inc. (BIIB) / Tysabri (Natalizumab)</b>						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Elan Corporation, plc (ADR) (ELN) / Tysabri (Natalizumab)</b>						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	<u>01/11/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>ZymoGenetics, Inc. (ZGEN) / rThrombin</b>						
	Reduce Bleeding During Surgery/Critical Care (Hemostat)	Coagulating Agents (Coagulants)	<u>01/17/2008</u>	Yes	<b>Yes</b> Thrombin JMI / (KG) Evithrom (Human Thrombin) / (OMRI)	Yes
<b>Cardiome Pharma Corp.(USA) (CRME) / RSD1235 I.V. (Vernakalant)</b>						
	Acute Conversion Of Atrial Fibrillation	Sodium Channel Blocking Agents/Potassium Channel Blocking Agents	<u>01/18/2008</u>	Yes	<b>Yes</b> Lanoxin (Digoxin) / (GSK)	Yes
<b>Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Pulzium (Tedisamil)</b>						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
	Atrial Fibrillation, Atrial Flutter	Potassium Channel Blocking Agents	<u>01/18/2008</u>	Yes	<b>Yes</b> Azimilide / (PG) Tikosyn (Dofetilide) / (PFE)	No
<b>Johnson &amp; Johnson (JNJ) / Tibotec TMC125 (Etravirine)</b>						
	Treatment Of HIV-1 Infection In Combination With Other Antiretroviral Agents	Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)	<u>01/18/2008</u>	No	<b>Yes</b> Rescriptor (Delavirdine Mesylate) / (PFE) Sustiva (Efavirenz) / (BMJ)	No
<b>MiddleBrook Pharmaceuticals, Inc. (MBRK) / Amoxicillin PULSYS</b>						
	Acute Pharyngitis/Tonsillitis (Strep Throat) In Adults And Adolescents Due To Group A Streptococcal Infections	Penicillin Derivatives	<u>01/23/2008</u>	Yes	<b>Yes</b> Amoxil (Amoxicillin) / (GSK)	No
<b>Roche Holding Ltd. (ADR) (RHHBY) / Xeloda (Capecitabine)</b>						
	First-Line Or Second-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer) In Combination With Eloxatin (Oxaliplatin) And With Or Without Avastin (Bevacizumab)	Pyrimidine Analogs	01/25/2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Cervarix (HPV16/HPV18 Vaccine)</b>						
	Human Papillomavirus (HPV) Vaccine, Cervical Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	01/29/2008	Yes	<b>Yes</b> Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine) / (MRK)	No
<b>Progenics Pharmaceuticals, Inc. (PGNX) / MNTX (Subcutaneous Methylnaltrexone)</b>						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>01/30/2008</u>	No	<b>Yes</b> Entereg (Alvimopan) / (ADLR)	Yes
<b>Wyeth (WYE) / MNTX (Subcutaneous Methylnaltrexone)</b>						
	Opioid-Induced Constipation (OIC) In Patients Receiving Palliative Care	Opioid Receptor Antagonists	<u>01/30/2008</u>	No	<b>Yes</b> Entereg (Alvimopan) / (ADLR)	No








Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## February Drug Candidates

### Companies

**Abbott Laboratories (ABT) [2]**  
 Adolor Corporation (ADLR)  
 AstraZeneca plc (ADR) (AZN)  
 Axcan Pharma Inc. (USA) (AXCA)  
 Genentech, Inc. (DNA)  
**GlaxoSmithKline plc (ADR) (GSK) [2]**  
 Merck & Co., Inc. (MRK)  
 Regeneron Pharmaceuticals, Inc. (REGN)  
 Roche Holding Ltd. (ADR) (RHHBY)  
 sanofi-aventis (ADR) (SNY)

### Sectors

**I** Biopharmaceuticals  
 Dermatology  
 Digestive System  
 Hematology  
 Immunology  
 Infectious Diseases  
 Oncology  
 Surgery

#### Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [ ].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
<b>Abbott Laboratories (ABT) / Humira (Adalimumab)</b>						
	Moderate To Severe Chronic Plaque Psoriasis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	02/01/2008	Yes	<b>Yes</b> Centocor Remicade (Infliximab) / (JNJ) Enbrel/Enbrel Once-Weekly (Etanercept) / (AMGN)	No
<b>Axcan Pharma Inc. (USA) (AXCA) / Ultrase (Pancrelipase)/Ultrase MT (Pancrelipase)</b>						
	Chronic Pancreatitis, Exocrine Pancreatic Insufficiency, Pancreatic Deficiency Related To Cystic Fibrosis (CF)	Enzyme Replacement Therapy	02/01/2008	Yes	<b>No</b> Multiple Drugs	No
<b>AstraZeneca plc (ADR) (AZN) / Humira (Adalimumab)</b>						
	Moderate To Severe Chronic Plaque Psoriasis	Tumor Necrosis Factor-Alpha Antagonists (TNF-Alpha Antagonists)	02/01/2008	Yes	<b>Yes</b> Centocor Remicade (Infliximab) / (JNJ) Enbrel/Enbrel Once-Weekly (Etanercept) / (AMGN)	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Kinrix (Diphtheria, Tetanus, Acellular Pertussis-Inactivated Polio Virus Vaccine (DTaP-IPV))</b>						
	Diphtheria, Tetanus, Acellular Pertussis And Polio Vaccine	Diphtheria/Tetanus/Acellular Pertussis (DTaP)	February 2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>GlaxoSmithKline plc (ADR) (GSK) / Entereg (Alvimopan)</b>						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>02/08/2008</u>	No	<b>Yes</b> MNTX (Subcutaneous Methylnaltrexone) / (PGNX)	No
<b>Adolor Corporation (ADLR) / Entereg (Alvimopan)</b>						
	Post-Operative Ileus (POI)	Opioid Receptor Antagonists	<u>02/08/2008</u>	No	<b>Yes</b> MNTX (Subcutaneous Methylnaltrexone) / (PGNX)	Yes
<b>Merck &amp; Co., Inc. (MRK) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)</b>						
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>sanofi-aventis (ADR) (SNY) / Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)</b>						
	Vaginal And Vulvar Cancer Vaccine	Papillomavirus, Papillomavirus Vaccines	02/15/2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Abbott Laboratories (ABT) / KOS Pharmaceuticals Simcor (Niacin/Simvastatin)</b>						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 <sup>st</sup> /2 <sup>nd</sup> Drug?
	Hypercholesterolemia, Dyslipidemia	Free Fatty Acid Inhibitors/HMG CoA Reductase Inhibitors (Statins)	02/20/2008	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Genentech, Inc. (DNA) / Avastin (Bevacizumab)</b>						
	First-Line Treatment Of Locally Recurrent Or Metastatic Breast Cancer In Combination With Chemotherapies	Monoclonal Antibodies	<u>02/22/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Roche Holding Ltd. (ADR) (RHHBY) / Avastin (Bevacizumab)</b>						
	First-Line Treatment Of Locally Recurrent Or Metastatic Breast Cancer In Combination With Chemotherapies	Monoclonal Antibodies	<u>02/22/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	No
<b>Regeneron Pharmaceuticals, Inc. (REGN) / Riloncept (Interleukin-1 Cytokine Trap)</b>						
	CIAS1-Associated Periodic Syndrome (CAPS)	Interleukin-1 Receptor Antagonists (IL-1 Antagonists)	<u>02/29/2008</u>	Yes	<b>Yes</b> Only Candidate with This PMOA for This Indication	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1<sup>st</sup>/2<sup>nd</sup> Drug** -- 1st or 2nd FDA Approved Drug of the Company?

## Price and Financial Info

### December 2007

Data as of 11/29/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
BioMarin Pharmaceutical Inc.	BMRN	27.55	2,667.260	1,467,936	18.41	327.06	588.6	58.70%	62.48%
DOV Pharmaceutical, Inc.	DOVP	0.23	25.473	167,906	2.03	0	10.6	4.55%	8.33%
Jazz Pharmaceuticals, Inc.	JAZZ	15.47	379.797	29,005	13.55	62.01	130.9	n/a	
Ligand Pharmaceuticals Inc.	LGND	4.87	464.761	551,056	12.03	6.99	98.4	-55.03%	-51.24%
Neurocrine Biosciences, Inc.	NBIX	11.91	452.543	754,651	1.85	20.46	124.8	25.50%	29.29%
Pharmacyclics, Inc.	PCYC	2.01	52.196	124,433	1.62	0	32.3	-65.16%	-61.38%
Solvay S.A. (ADR)	SVYSY	144.30	12,222.373	643	3.44	43.96	613.3	1.33%	5.12%
Wyeth	WYE	49.00	65,617.859	8,168,864	5.25	69.12	12,919.1	1.89%	5.68%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### January 2008

Data as of 11/29/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Biogen Idec Inc.	BIIB	72.66	21,316.213	3,851,292	16.48	31.25	671.3	41.06%	44.85%
Cardiome Pharma Corp.(USA)	CRME	10.01	637.863	771,784	7.62	0	85.9	-16.93%	-13.14%
Elan Corporation, plc (ADR)	ELN	22.39	10,467.002	2,407,780	n/a	0	805.9	53.57%	57.35%
GlaxoSmithKline plc (ADR)	GSK	52.14	144,027.681	1,779,506	13.44	69.63	6,491.4	-2.08%	1.70%
Johnson & Johnson	JNJ	68.28	195,400.286	13,101,928	13.89	18.12	8,320.0	3.14%	6.93%
MiddleBrook Pharmaceuticals, Inc.	MBRK	1.05	49.061	55,489	n/a	153.16	5.9	-73.75%	-69.96%
Omxix Biopharmaceuticals, Inc.	OMRI	33.01	559.499	273,630	4.91	0.55	85.4	4.99%	8.78%
Progenics Pharmaceuticals, Inc.	PGNX	19.85	589.723	392,573	3.74	0	145.7	-28.05%	-24.27%
Roche Holding Ltd. (ADR)	RHHBY	96.70	166,819.594	157,844	6.20	17.99	20,828.3	6.91%	10.70%
Sciele Pharma Inc.	SCRX	21.44	764.305	1,206,735	611.44	76.59	204.2	-4.75%	-0.97%
SkyePharma PLC (ADR)	SKYEY	2.93	238.792	6,481	n/a	1,434.57	47.0	-30.90%	-27.11%
Solvay S.A. (ADR)	SVYSY	144.30	12,222.373	643	3.44	43.96	613.3	1.33%	5.12%
Spectrum Pharmaceuticals, Inc.	SPPI	3.15	98.345	313,304	1.66	0	65.8	-39.19%	-35.40%
Wyeth	WYE	49.00	65,617.859	8,168,864	5.25	69.12	12,919.1	1.89%	5.68%
ZymoGenetics, Inc.	ZGEN	14.70	1,006.995	476,177	6.87	45.75	198.5	-8.35%	-4.57%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

### February 2008

Data as of 11/29/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Abbott Laboratories	ABT	56.94	87,987.790	5,567,208	1,030.37	78.44	2,549.0	21.74%	25.53%
Adolor Corporation	ADLR	3.82	175.794	389,327	1.46	0	147.5	-51.40%	-47.61%
AstraZeneca plc (ADR)	AZN	46.85	68,773.454	1,194,165	n/a	98.52	3,530.0	-20.00%	-16.21%
Axcan Pharma Inc. (USA)	AXCA	22.61	1,250.250	588,418	4.61	0.12	268.8	53.29%	57.08%
Genentech, Inc.	DNA	76.27	80,319.250	3,096,712	9.08	20.17	2,920.0	-7.25%	-3.46%
GlaxoSmithKline plc (ADR)	GSK	52.14	144,027.681	1,779,506	13.44	69.63	6,491.4	-2.08%	1.70%

Merck & Co., Inc.	MRK	59.86	130,289.304	13,991,366	7.04	28.22	7,391.5	34.34%	38.12%
Regeneron Pharmaceuticals, Inc.	REGN	21.02	1,390.468	551,024	9.18	132.1	397.0	-2.23%	1.56%
Roche Holding Ltd. (ADR)	RHHBY	96.70	166,819.594	157,844	6.20	17.99	20,828.3	6.91%	10.70%
sanofi-aventis (ADR)	SNY	46.44	126,264.279	1,508,915	n/a	n/a	n/a	5.50%	9.29%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,